Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Tuesday

Atossa Therapeutics (NASDAQ:ATOS) is expected to be issuing its quarterly earnings data on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Atossa Therapeutics Stock Performance

Shares of ATOS stock opened at $0.75 on Friday. The company has a market capitalization of $94.83 million, a P/E ratio of -3.43 and a beta of 1.20. The company’s 50 day moving average price is $0.81 and its two-hundred day moving average price is $1.12. Atossa Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.31.

Hedge Funds Weigh In On Atossa Therapeutics

An institutional investor recently raised its position in Atossa Therapeutics stock. Bank of America Corp DE lifted its position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the quarter. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. Institutional investors own 12.74% of the company’s stock.

Wall Street Analysts Forecast Growth

ATOS has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a report on Wednesday, March 12th. Ascendiant Capital Markets raised their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.